VC-backed Zymeworks strikes optional merger deal with Kairos
Zymeworks Inc, which this week raised US$61.5 million in Series A financing, has entered into an optional merger agreement with Kairos Therapeutics Inc, a Vancouver-based specialist in antibody drug conjugates. The deal, announced concurrently with a strategic partnership between the two companies, would integrate their respective platforms, resources and pipelines to accelerate the development of novel anti-cancer biotherapeutics. As part of the strategic partnership, Vancouver-based Zymeworks announced it has made an undisclosed equity investment in Kairos. BDC Capital and Lumira Capital led the company's Series A round.
8 January 2016•4 mins read
